SNDX Syndax Pharmaceuticals, Inc.

$18.18▼ -3.40% Healthcare Other
After hours $18.05▼ -0.72% Sep 11, 7:30 PM ET
Volume 1.22M Avg Volume (10D) 1.39M
Key Metrics & Fundamentals
Market Cap
$1.62B
P/E Ratio
–
Div Yield
–%
52W Range
12.99 - 25.59
% vs 50 MA
-12.44%
% vs 200 MA
-13.49%
RSI-14
35.2
MACD Histogram
-0.1200
Beta (1Y vs SPY)
0.61
Free Cash Flow
-$30.31M
Gross Rev
$72.79M
Gross Profit
$69.58M
EBITDA
-$36.68M
COGS
$3.21M
Operating Exp
$109.58M
Operating Income
-$40.00M
EBIT
-$40.00M
Pretax Income
-$49.36M
Net Income
-$49.36M
EPS (Diluted)
-0.55
Price & Volume History
Loading chart…
Recent News
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire · Sep 4, 2026 8:01 PM
Syndax Announces Participation in September Investor Conferences
GlobeNewswire · Sep 1, 2026 11:00 AM
Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks
TipRanks · Aug 22, 2026 6:05 PM
UBS Adjusts Price Target on Syndax Pharmaceuticals to $33 From $37, Keeps Buy Rating
MT Newswires · Aug 21, 2026 12:26 PM
Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?
Insider Monkey · Aug 12, 2026 9:35 PM
Syndax (SNDX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 12, 2026 2:45 AM
How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors
Simply Wall St. · Aug 7, 2026 2:18 PM
Syndax Pharmaceuticals Inc (SNDX) (Q2 2026) Earnings Call Highlights: Revenue Surges 92% as ...
GuruFocus.com · Aug 5, 2026 5:04 AM
Syndax Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · Aug 5, 2026 3:03 AM
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 4, 2026 9:15 PM
Financial Overview - Income Statement Quarterly

See SNDX's money flow as a full page

Social Sentiment
Avg +0.70 · 2 posts
DDPriceTargetDiscussionSyndax Pharmaceuticals a promising commercial biotech with multiple approved drugs - Price target $20-56 (M&A possible)
r/wallstreetbets · Nov 9, 2025
The author is actively invested and expresses a bullish outlook, highlighting commercial products and a large cash balance.
positive +0.80
NewsTradeDDSNDX straddle
r/wallstreetbets · Aug 28, 2024
The discussion around a potential FDA approval suggests optimism regarding the stock's future.
positive +0.60
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙